Circulating Tumor DNA Profiling Defines Risk In Patients With Ewing Sarcoma

This study focuses on improving how doctors evaluate risk for patients diagnosed with Ewing Sarcoma. Traditionally, doctors relied mostly on imaging scans and physical factors (like tumor size or whether the cancer had spread) to figure out how aggressive the cancer might be. In this research, scientists evaluated simple blood samples using a technology that detects fragments of DNA shed by cancer cells into the bloodstream, known as circulating tumor DNA (ctDNA). They tested ctDNA before treatment and throughout therapy in hundreds of young patients to see if these floating DNA fragments could provide a clearer picture of each patient’s risk.

The researchers discovered that measuring ctDNA in the blood is a strong indicator of how well a patient will respond to treatment. Higher levels of tumor DNA before starting treatment were linked to worse outcomes, as were specific genetic mutations (like TP53) or tumor DNA that remained in the blood during therapy. By combining these blood test results with traditional tumor characteristics, doctors can now categorize patients into distinct low-, intermediate-, and high-risk groups far more accurately. Ultimately, this allows medical teams to tailor treatments more precisely—potentially avoiding overly harsh therapies for low-risk patients while giving high-risk patients stronger or newer targeted options sooner.

Read the full article